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The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) path-
way is activated in the majority of human cancers.This pathway is known to play a key role
in numerous cellular functions including proliferation, adhesion, migration, invasion, metab-
olism, and survival, but in the current review we focus on its role in angiogenesis. PI3K
activationmay occur via RASmutation, loss of phosphatase and tensin homolog (PTEN ), or
by increased expression of growth factor receptors such as epidermal growth factor recep-
tor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to
HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor
(VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor
cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) depen-
dent and independent mechanisms.The PI3K/AKT pathway also modulates the expression
of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors
targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been
shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on
tumor vasculature can be difﬁcult to predict. The vasculature of tumors is aberrant, leading
to sluggish bloodﬂow and elevated interstitial blood pressure, which can be perpetuated by
the high levels of VEGF. Hence, decreasing VEGF expression can paradoxically lead to vas-
cular normalization and improved bloodﬂow in some tumors. In addition to its importance
in cancer, the PI3K pathway also plays an essential role in the formation of normal blood
vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K
develop vascular defects. Stimulation of endothelial cells byVEGF leads to activation of the
PI3K pathway within these cells, which is important for cell migration. Sustained endothe-
lial activation of AKT1 has been shown to induce the formation of structurally abnormal
blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway
plays an important role in regulating angiogenesis both in normal tissues and in cancers.
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INTRODUCTION
The PI3K/AKT pathway is important not only in the develop-
ment of cancers but also for signaling in normal cells. This path-
way is known to play a key role in numerous cellular functions
including proliferation, adhesion, migration, invasion, metabo-
lism, and survival (Bader et al., 2005), but in the current review we
focus on its role in angiogenesis. Phosphatidylinositol 3-kinases
(PI3K) are a family of enzymes that phosphorylate the 3′-OH of
the inositol ring of phosphatidylinositol. There are three classes
of PI3K: I, II, and III. Class I PI3Ks are heterodimers com-
posed of a catalytic and a regulatory subunit and are further
subdivided into two subclasses: IA and IB. Class II PI3Ks con-
sists of three members, P13KC2α, Pl3KC2β, and P13KC2γ, while
Class III contains only one member encoded by the gene VpS34
(Rodriguez-Viciana et al., 1994; Toker and Cantley, 1997; Fru-
man et al., 1998). Phosphatidylinositol 3,4,5-triphosphate (PIP3)
is an important lipid second messenger generated by PI3K,
which plays a vital role in several signal transduction pathways
(Whitman et al., 1988; Toker and Cantley, 1997). PIP3 activates
the serine/threonine kinases PDKl and AKT. The phosphatase
and tensin homolog (PTEN ) gene encodes a phosphatase that
opposes the action of PI3K, thereby reducing the level of acti-
vated AKT. AKT controls protein synthesis and cell growth by
leading to the phosphorylation of mammalian target of rapamycin
(mTOR).
Vascular endothelial growth factor (VEGF) is a potent angio-
genic factor whose effects on endothelial cells are mediated
in part by the PI3K pathway. The mammalian VEGF fam-
ily is comprised of ﬁve members: VEGFA, VEGFB, VEGFC,
VEGFD, and placenta growth factor (PGF), the best character-
ized of which is VEGFA, commonly referred to as simply VEGF.
A number of proteins structurally related to VEGF have also
been discovered encoded by parapoxviruses (VEGFE) and in
snake venom (VEGFF). The VEGF ligands can bind to three
type III receptor tyrosine kinases: VEGFRl/FLT1, VEGFR2/KDR,
and VEGFR3/FLT4, of which VEGFR2 has the most important
role in VEGF-induced angiogenesis (Ellis and Hicklin, 2008).
VEGFA, B and PGF can bind to VEGFR1. VEGFA and E bind
to VEGFR2, while VEGFC and D bind to VEGFR3 (Olsson et al.,
2006).
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TUMOR VASCULATURE AND REGULATION OF VEGF BY
HYPOXIA
The vasculature of tumors is aberrant, resulting in heterogene-
ity in the tumor microenvironment with variation in oxygen
concentration, nutritional factors, and metabolic waste products
(Vaupel et al., 1989). Tumor angiogenesis results from an imbal-
ance between pro-angiogenic factors such as VEGF and endoge-
nous anti-angiogenic factors such as angiostatin and endostatin
(Folkman, 2002; Nieder et al., 2006). Tumor cells vary in their
angiogenic potential, and angiogenic tumor cells generally secrete
more bFGF and VEGF than non-angiogenic ones (Naumov et al.,
2006). Elevated levels of VEGF can increase vascular permeability,
leading to leaky vessels, sluggish bloodﬂow,and elevated interstitial
pressure.
One of the most potent stimuli for increased VEGF produc-
tion by tumor cells is hypoxia, which commonly occurs in tumors.
Hypoxia leads to the induction of hypoxia-inducible factor 1 (HIF-
1), a bHLH–PAS transcription factor that consists of both an α
and a β subunit (Ratcliffe et al., 2000; Semenza, 2003). Decreased
pO2 increases HIF-1α stability through post-translational mod-
iﬁcation of the protein. Once stabilized, the α subunit binds to
the β subunit, which is constitutively present. This heterodimer
then binds to numerous promoters containing hypoxia response
elements (HREs), leading to the transcription of dozens of target
genes including VEGF (Forsythe et al., 1996). HIF-1α is upreg-
ulated across a broad range of cancers, and HIF regulates key
features of tumor biology such as angiogenesis, invasion, and
glucose metabolism (Ratcliffe et al., 2000; Semenza, 2003).
Studies have shown that binding of both STAT3 and HIF-1α
to the VEGF promoter is essential for maximum transcription of
VEGF mRNA under hypoxia (Gray et al., 2005). STAT3 signaling
is required for VEGF and PI3K/AKT mediated HIF-1α expres-
sion. Blocking STAT3 by the small molecule inhibitor, CPA-7 or
STAT3 siRNA abolished both HIF-1 and VEGF expression (Xu
et al., 2005). EGF-induced STAT3 binding to the VEGF promoter
can be blocked by the PI3K inhibitor, LY294002, or STAT3 siRNA
in colorectal cancer cells (Cascio et al., 2009).
EGFR/PI3K/mTOR PATHWAY, HIF, AND VEGF
While hypoxia is the primary stimulus for HIF-1α upregulation,
activationof the epidermal growth factor receptor (EGFR),and the
PI3K pathway can also contribute to increased HIF-1α (Figure 1).
EGFR is a transmembrane receptor tyrosine kinase that belongs to
the HER family of receptors. It is overexpressed and activated in a
variety of cancers and provides an attractive target for anti-cancer
therapy (Dutta and Maity, 2007). Zhong et al. (2000) were among
the ﬁrst to show that activation of the EGFR/PI3K/AKT/mTOR
pathway could increaseVEGF expression by upregulating HIF-1α.
PI3K/mTOR pathway activation increases HIF-1α protein lev-
els without altering HIF-1α mRNA levels (Jiang et al., 2001),
presumably by increasing HIF-1α translation (Laughner et al.,
2001).
Work from our own lab has shown that in U87MG human
glioblastoma cells,EGFRactivation can also increaseVEGFexpres-
sion by transcriptional activation of theVEGFpromoter via a PI3K
dependent pathway that is independent of HIF-1 (Maity et al.,
2000). We have also shown that EGFR ampliﬁcation and PTEN
FIGURE 1 | PI3K/AKT/mTOR pathway in angiogenesis. PI3K activation
may occur via RAS mutation, by increased expression of growth factor
receptors such as EGFR or by loss of PTEN. Activation of the
PI3K/AKT/mTOR pathway can increase VEGF secretion. The PI3K/AKT
pathway also modulates the expression of other angiogenic factors such as
nitric oxide and angiopoietins.
mutation had an additive effect in increasing the VEGF promoter
activity in human glioblastoma cells (Pore et al., 2003).
Pharmacological inhibition of EGFR can decrease VEGF
expression and reduce angiogenesis in many tumor types (Per-
rotte et al., 1999; Ciardiello et al., 2001; Huang et al., 2002; Pore
et al., 2006b).One of the initial reports examining EGFR inhibitors
found that the anti-EGFR antibody C225 could decrease not only
levels of VEGF mRNA and protein but that of other angiogenic
factors such as interleukin 8 and bFGF (Petit et al., 1997; Per-
rotte et al., 1999). One report showed that cells could acquire
resistance to this antibody by selection of tumor cell subpopu-
lations with increased angiogenic potential (Viloria-Petit et al.,
2001). The consequences of decreasing VEGF by blocking EGFR
signaling may be complicated. We have also shown that target-
ing tumor cells with the EGFR inhibitor erlotinib may improve
vascular ﬂow by causing vascular normalization, hence leading
to improved response to chemotherapy and radiation (Cerniglia
et al., 2009).
Epidermal growth factor receptor activationmayhave effects on
VEGF expression independent of PI3K. A recent study exploring
the role of MAPK and PI3K signaling in angiogenesis in squamous
cell carcinoma of the head and neck found that EGFR activation
induces VEGFA expression that requires both PI3K and MAPK
signaling whereas VEGFC expression is dependent on MAPK, and
not the PI3K–mTOR pathway (Luangdilok et al., 2011).
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Another common mechanism of PI3K activation within
tumors is through loss of PTEN which in glioblastomas results
in increased VEGF expression mediated by HIF-1α stabiliza-
tion (Zundel et al., 2000). PTEN loss is also seen in advanced
prostate cancers. PTEN siRNA transfected pancreatic cancer cells
have higher levels of secreted VEGF and are highly prolifera-
tive (Ma et al., 2009). Overexpression of wildtype PTEN in PC3
prostate cancer cells, which have PTEN mutations, inhibits angio-
genesis, and tumor growth (Fang et al., 2007). A recent study
exploring the role of PTEN in hepatocellular carcinoma also
found similar inhibition of angiogenesis. Interestingly, this study
also suggested that PTEN regulates angiogenesis through both
phosphatase-dependent and independentmechanisms (Tian et al.,
2010).
RAS SIGNALING AND VEGF
The RAS family of GTPases (H-RAS,N-RAS, and K-RAS) plays an
important role in various cellular functions, including prolifera-
tion, differentiation, and apoptosis. Mutations in H-RAS, K-RAS,
and N-RAS convert them into oncogenes, which commonly occur
in various cancers (Bos, 1989). Expression of mutant K-RAS or H-
RAS has been associated with increased VEGF expression (Grugel
et al., 1995; Rak et al., 1995). Mazure et al. (1997) showed that
induction of VEGF by hypoxia is modulated by a PI3K/AKT path-
way in H-RAS transformed cells through a HIF-1 transcriptional
element. Introduction of oncogenic H-RAS into immortalized
endothelial cells increases their angiogenic potential and results
in increased VEGF expression. This angiogenic potential could be
only partially inhibited by PI3K inhibition, indicating that RAS
mediated angiogenesis through a PI3K-independent mechanism
as well (Arbiser et al., 1997). H-RAS was found to play an impor-
tant role in angiogenesis in skin carcinogenesis. In this model,
H-RAS was responsible not only for VEGF induction, but also for
inducing the expression of other angiogenic factors such as PGF
and angiopoietin-2 (Larcher et al., 1996, 2003). Work from our
lab has shown that H-RAS upregulates Glut1 promoter activity, at
least in part, by increasing HIF-1α protein and that this involves
the PI3K pathway (Chen et al., 2001).
ROLE OF PI3K IN NORMAL DEVELOPMENT AND
ENDOTHELIAL CELLS
The PI3K pathway also plays an essential role in the forma-
tion of normal blood vessels during development. Embryos with
kinase-dead p110α catalytic subunit of PI3K develop gross vascu-
lar defects, indicating that this subunit is essential for endothelial
cell migration and angiogenesis (Graupera et al., 2008). The same
study showed that p110α controls endothelial cell migration by
positively regulating RhoA in endothelial cells. The p110α sub-
unit also regulates barrier function and junctional morphology of
endothelial cells. Only the p110α subunit decreased TNF-induced
endothelial cell permeability, Tyr phosphorylation of the adherens
junction protein vascular endothelial cadherin, and leukocyte
transendothelial migration (Cain et al., 2010).
When VEGF binds to its receptor on normal endothelial cells,
the RAS and PI3K pathways are activated. One study tried to iden-
tify vascular signaling in response to H-RAS and its immediate
effectors by activating either the ERK/MAPK or PI3K pathways in
primary endothelial tissues (Serban et al., 2008). Constitutive acti-
vation of the ERK/MAPK pathway could induce angiogenesis but
not vascular permeability, while activation of PI3K was required
for both angiogenesis and vascular permeability. Pharmacological
inhibition of PI3K (α/β) suppressed both RAS or VEGF medi-
ated vascular response in vivo and survival of primary endothelial
cells in vitro. However, inhibition of PI3K (γ/δ) suppressed RAS
or VEGF mediated vascular permeability in vivo, with no effect on
the survival of primary endothelial cells.
Phosphatase and tensin homolog, a phosphatase that negatively
regulates PI3K, has been found to be indispensable for normal
cardiovascular homeostasis. PTEN-deﬁcient endothelial cells dis-
play increased angiogenesis and tumorigenesis (Hamada et al.,
2005). The PDKl kinase is an essential player in the PI3K path-
way, phosphorylating AKT on the T308 residue. PDKl is vital to
endothelial cell migration in response to VEGF stimulation in
a PI3K-dependent manner (Primo et al., 2007). The study also
identiﬁed that phosphorylation at T308 is more important than at
S473.
A recent study found that attenuating the expression of RACKl,
a ubiquitously expressed scaffolding protein, with siRNA sup-
pressed theVEGF/PI3K/AKT driven migration of endothelial cells
(Wang et al., 2011). Survivin, an anti-apoptotic protein, is also
regulated by the PI3K pathway (Martinelli et al., 2006; Zhao et al.,
2010) and is upregulated in endothelial cells in response to VEGF
(Tran et al., 1999). Lack of survivin in endothelial cells has been
shown to result in embryonic defects in angiogenesis (Zwerts
et al., 2007). VEGF and survivin can act as chemoprotectants in
endothelial cells, protecting them from drug-induced dell death.
This chemoprotective role requires an active PI3K/AKT pathway
(Tran et al., 2002).
Sustained endothelia1 activation of AKTl has been shown to
induce the formation of structurally and functionally abnormal
blood vessels that recapitulate the aberrations of tumor vessels
(Phung et al., 2006). This study also showed that inhibition of AKT
signaling by rapamycin could inhibit the pathological vasculariza-
tion. In a recent study, sustained RAS activation in endothelial cells
bypassed senescence and resulted in abnormal vascular morpho-
genesis, an effect that was regulated by PI3K signaling (Bajaj et al.,
2010).
Ephrins and their receptor tyrosine kinases play signiﬁcant roles
in various processes such as vascular development, cell migra-
tion, and angiogenesis. There are two classes of Eph receptors,
A and B. Class A receptors usually bind to GPI anchored ephrin
A ligands, and class B receptors bind to transmembrane-linked
ephrin B ligands. Binding of ephrin to the Eph receptor results
in bidirectional signaling between the receptor-carrying cell and
the ligand-producing cell (Pitulescu and Adams, 2010). Ephrin B2
controls the internalization of VEGFR2 and VEGFR3, a process
that is crucial for the growth of blood vessels (Sawamiphak et al.,
2010; Wang et al., 2010). In the absence of ligands, EphA2 recep-
tor can be phosphorylated by AKT, promoting cell migration
while in the presence of Ephrin A1, both AKT and the EphA2
receptor are dephosphorylated, preventing cell migration (Miao
et al., 2009). Slit and Robo proteins are regulators of vascular
remodeling. Slit 2 protein canpromote angiogenesis viamTORC2-
dependent activation of AKT and RAC. However, this process is
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inhibited in the presence of Ephrin A1, suggesting that the sig-
naling between Ephrin A1 and Slit can regulate angiogenesis and
vascular homeostasis (Dunaway et al., 2011).
PI3K/AKT AND NITRIC OXIDE
The PI3K/AKT pathway has also been implicated in angiogenesis
through its regulation of nitric oxide (NO) signaling in endothelial
cells.Nitric oxide synthesis is regulated by the enzymeNOsynthase
(NOS). There are three isoforms of NOS, of which nNOS/NOS1
and eNOS/NOS3 are constitutively expressed, while expression of
the third isoform, iNOS/NOS2, is inducible. Tumor cells mostly
express iNOS,but some tumor types also express eNOSandnNOS.
Tumor vascular endothelial cells mostly express eNOS, while the
tumor associated stromal ﬁbroblasts and immune cells express
iNOS (Fukumura et al., 2006).
Studies using eNOS−/− and iNOS−/− mice have shown that
eNOS plays a key role in VEGF-induced angiogenesis and vas-
cular permeability (Fukumura et al., 2001). VEGF stimulation of
endothelial cells is required for the migration of these cells and the
formation of capillary-like structures in a PI3K–AKT dependent
manner (Morales-Ruiz et al., 2000). Earlier studies have shown
that VEGF can induce NO production, which is attenuated by
PI3K inhibitors (Papapetropoulos et al., 1997). This regulation
may occur via phosphorylation of eNOS at the serine 1177 residue
by AKT (Dimmeler et al., 1999; Fulton et al., 1999). This phos-
phorylation is required for VEGF-induced endothelial cell migra-
tion (Dimmeler et al., 2000). Hypoxia can also increase eNOS
phosphorylation via HSP9O binding to eNOS and activation of
the PI3K/AKT pathway (Chen and Meyrick, 2004). Another link
between the NO pathway and angiogenesis is suggested by the
fact that NO donors can increase the expression and transcrip-
tional activity of HIF-1, thus resulting in the induction of VEGF
mRNA (Kasuno et al., 2004). The same study reported that target-
ing the PI3K pathway using LY294002 or rapamycin inhibited the
expression of HIF-1 dependent reporter gene induced by the NO
donor.
ANGIOPOIETINS
In addition to VEGF, another class of growth factors having
angiogenic activity includes the angiopoietins and their receptors,
especially the ANGl/TIE2 system. Angiopoietin 1 and 2 (ANG1
and 2) bind to TIE2 receptor tyrosine kinase, which is expressed
primarily on endothelial cells.WhileANGl is required for endothe-
lial development, ANG2 is an antagonist of the ANGl/TIE2 sys-
tem and can disrupt blood vessel formation (Davis et al., 1996;
Maisonpierre et al., 1997). However, some reports also suggest that
ANG2 can be pro-angiogenic in some circumstances. ANG2 can
promote proliferation and migration of endothelial cells, sprout-
ing, and neovascularization in the presence of VEGF (Asahara
et al., 1998; Lobov et al., 2002). A study using ANGl or ANG2
inhibitors reported that while ANG1 inhibition had little effect
on the tumor vasculature, ANG2 inhibition resulted in decreased
tumor vascularity and allowed for unrestricted ANGl activity,
leading to vessel normalization. The ANGl–ANG2 inhibitor com-
bination did not affect the ANG2-mediated inhibition of vascu-
lature but prevented tumor vessel normalization (Falcon et al.,
2009).
ANG1 can promote endothelial cell survival through activa-
tion of the PI3K pathway (Kim et al., 2000a), and similar results
could be achieved with higher concentrations of ANG2 (Kim et al.,
2000b). A recent study by Yuan et al. (2009) showed that ANG2
can act as an agonist of the TIE2 receptor in the absence of ANGl
and can activate the PI3K–AKT pathway, although with weaker
potency than ANGl. ANGl has been shown to stimulate TIE2,
AKT, and eNOS phosphorylation in HUVECs in a PI3K depen-
dent manner (Babaei et al., 2003). Another study reported that
HSP90 binding to eNOS and activation of the PI3K pathway con-
tribute to ANGl induced eNOS phosphorylation, NO production,
and angiogenesis in coronary artery endothelial cells (Chen et al.,
2004). Mice lacking the p110α catalytic subunit of PI3K display
vascular defects along with reduced TIE2 protein levels (Lelievre
et al., 2005). It has been shown that association between p85
subunit of PI3K and TIE2 is essential for PI3K activity (Kontos
et al., 1998). ANGl can induce localization of TIE2 to endothe-
lial cell–cell contacts, however in isolated cells TIE2 localizes to
cell–substratum contacts (Fukuhara et al., 2008; Saharinen et al.,
2008). TIE2 activation at cell–cell contacts leads to the activation
of AKT, which results in phosphorylation of eNOS and inhibition
of FOXO1 (Fukuhara et al., 2008). FOXO1 regulates the expression
of genes involved in apoptosis such as survivin and also regulates
the expression of ANG2 (ANG1 antagonist) in endothelial cells,
suggesting the importance of ANGl in maintaining blood vessel
stability (Daly et al., 2004). The ANG1–TIE2 association also reg-
ulates the expression of D114, a Notch ligand involved in vascular
stability in a β-catenin dependent manner. PI3K–AKT inhibits
GSK3β leading to β-catenin stability and this potentiates Notch
signal-mediated D114 expression (Zhang et al., 2011).
PI3K/AKT/mTOR INHIBITORS
Inhibitors targeting the PI3K/AKT pathway have been developed
and, as predicted, these agents can decrease VEGF secretion and
angiogenesis. The traditional PI3K/AKT inhibitors LY294002 and
wortmannin exhibit anti-angiogenic activity. However, LY294002
and wortmannin are unsuitable for human use due to toxicity.
Newer PI3K inhibitors including SF1126 (Garlich et al., 2008),
ZSTK474 (Kong et al., 2009), andPI103 (Raynaud et al., 2007) have
displayed anti-angiogenic activity in xenograftmodels. TheNovar-
tis drug NVP-BEZ235, which is a dual PI3K and mTOR inhibitor
(Maira et al., 2008), blocked VEGF-induced neovascularization in
mice (Schnell et al., 2008), and inhibited the growth and prolifer-
ation of cancer cells with wild type and p110α mutations (Serra
et al., 2008). We have previously shown that nelﬁnavir, a HIV pro-
tease inhibitor can also inhibit AKT signaling and decrease VEGF
expression. Nelﬁnavir decreased the VEGF secretion under both
normoxic and hypoxic conditions (Pore et al., 2006a).
Inhibitors are also available against mTOR. mTOR kinase can
participate in two different complexes: mTORC1 (mTOR/Raptor)
and mTORC2 (mTOR/Rictor). Rapamycin is an mTORC1
inhibitor, and treatment with this agent or its analogs induces
insulin receptor substrate-1 expression, terminating the feed-
back inhibition of the pathway, and resulting in AKT activa-
tion (O’Reilly et al., 2006). However, with prolonged incuba-
tion, rapamycin may inhibit mTORC2 in certain cell types (Sar-
bassov et al., 2006). Rapamycin inhibits VEGF production and
Frontiers in Molecular Neuroscience www.frontiersin.org December 2011 | Volume 4 | Article 51 | 4
Karar and Maity PI3K/AKT/mTOR pathway in angiogenesis
has antiproliferative and antitumor activity (Zhong et al., 2000;
Guba et al., 2002). The drug has also been shown to inhibit
angiogenesis in vivo (Guba et al., 2002). The TSC2–TSC1 pro-
tein complex negatively regulates mTOR. TSC2-null cells have
high levels of HIF-1α and VEGF. Rapamycin treatment reduces
HIF-1α levels but fails to reduce VEGF levels completely in these
cells, indicating that TSC2 regulates VEGF through both mTOR-
dependent and -independent pathways (Brugarolas et al., 2003).
Treatment of myrAKT1mice (with sustainedAKTactivation)with
rapamycinhas been shown toblockbloodvessel formation (Phung
et al., 2006). The regulatory associated protein of mTOR (Raptor)
has been shown to interact with HIF-1α via an mTOR signal-
ing motif located in the N terminus of HIF-1α. HIF-1α lacking
this motif had impaired activity under hypoxia and was unable
to bind to the co-activator CBP/p300 (Land and Tee, 2007). The
dual mTORC1/mTORC2 inhibitors, OSI-027, and OXA-01 have
been shown to considerably reduce angiogenesis and regrowth
compared to rapamycin (mTORC1 inhibitor) alone. Combin-
ing these dual inhibitors with VEGFR antagonists was even more
efﬁcient in reducing tumor growth (Falcon et al., 2011).
SUMMARY
Activation of the PI3K/AKT/mTOR pathway in tumor cells can
increase VEGF secretion by both HIF-1 dependent and indepen-
dent mechanisms. This pathway can also regulate angiogenesis by
modulating expression of nitric oxide and angiopoietins. Many
agents have been developed that can inhibit PI3K and/or mTOR
signaling in tumor cells, and these drugs have effects on angiogen-
esis as well as on tumor cell proliferation and survival. Not only
is the PI3K/AKT/mTOR pathway commonly activated in tumor
cells, butVEGF binding to receptors on endothelial cells stimulates
this pathway which is essential for endothelial cell migration. For
this reason the PI3K/AKT pathway is essential for normal blood
vessel development during embryogenesis.
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